CD39 and CD73 in immunity and inflammation
Reads0
Chats0
TLDR
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, suggesting these ectoenzymes are novel therapeutic targets for managing a variety of disorders.About:
This article is published in Trends in Molecular Medicine.The article was published on 2013-06-01 and is currently open access. It has received 858 citations till now.read more
Citations
More filters
Journal ArticleDOI
Adenosine turnover (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
TL;DR: A multifunctional, ubiquitous molecule, adenosine acts at cell-surface G protein-coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase.
Dissertation
The Possible Roles of CD73 and Adenosine in the Osteoimmunological Bone Resorption of Periradicular Periodontitis
TL;DR: This work has shown that the role of nucleotides in RANKL mediated osteoclastogenesis and the loss of function effects on mouse periradicular lesion are related.
Dissertation
The identification and characterization of an intrinsic CD39/A2R-based regulatory mechanism that governs macrophage activation responses
TL;DR: This study demonstrates that inflammatory macrophage activation is inherently transient and that macrophages can reprogram themselves and offers new targets and strategies to more effectively treat myriad inflammatory and infectious diseases.
Journal ArticleDOI
Dys-regulation of peripheral transcript levels of ecto-5'-nucleotidase in multiple sclerosis patients.
Farzad Kobarfard,Rezvan Noroozi,Amirreza Dowlati Beirami,Mohammad Taheri,Soudeh Ghafouri-Fard +4 more
TL;DR: The role of NT5E in the pathogenesis of MS disease in male subjects is indicated and expression level of this gene might be used as a putative marker especially in male MS patients.
References
More filters
Journal ArticleDOI
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
K. G. M. M. Alberti,Paul Zimmet +1 more
TL;DR: A WHO Consultation has taken place in parallel with a report by an American Diabetes Association Expert Committee to re‐examine diagnostic criteria and classification of diabetes mellitus and is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements.
Journal ArticleDOI
How regulatory T cells work.
TL;DR: The hypothesis that effector T cells may not be 'innocent' parties in this suppressive process and might in fact potentiate TReg-cell function is proposed.
Journal ArticleDOI
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio,Karen M. Dwyer,Wenda Gao,David J. Friedman,Anny Usheva,Anna Erat,Jiang-Fan Chen,Keiichii Enjyoji,Joel Linden,Mohamed Oukka,Vijay K. Kuchroo,Terry B. Strom,Simon C. Robson +12 more
TL;DR: It is concluded that CD39 and CD73 are surface markers of T reg cells that impart a specific biochemical signature characterized by adenosine generation that has functional relevance for cellular immunoregulation.
Journal ArticleDOI
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression
Giovanna Borsellino,Markus Kleinewietfeld,Diletta Di Mitri,Alexander Sternjak,Adamo Diamantini,Raffaella Giometto,Sabine Höpner,Diego Centonze,Giorgio Bernardi,Maria Luisa Dell'Acqua,Paolo Maria Rossini,Luca Battistini,Olaf Rötzschke,Kirsten Falk +13 more
TL;DR: In humans CD39 is a marker of a Treg subset likely involved in the control of the inflammatory autoimmune disease and Notably, patients with the remitting/relapsing form of multiple sclerosis have strikingly reduced numbers of CD39(+) Treg cells in the blood.
Journal ArticleDOI
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
TL;DR: In the 10 years since the previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major changes in the recommendations, but there have been so many other developments that an update is needed.